DNA Biomed Solns (DNA) — Cash Flow-to-Debt Ratio
DNA Biomed Solns (DNA) has a Cash Flow-to-Debt Ratio of -0.16x as of June 2023, meaning its operating cash flow of ILA-265.00K could theoretically repay 0% of its total liabilities (ILA1.67 Million) in one year. See DNA FCF to total liabilities ratio to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
DNA Biomed Solns Cash Flow-to-Debt Ratio (2013–2024)
Historical debt coverage capacity for DNA Biomed Solns across 12 annual periods. For the full cash flow conversion analysis, see DNA cash flow conversion.
Annual Cash Flow-to-Debt Ratio for DNA Biomed Solns (2013–2024)
Year-by-year debt coverage analysis for DNA Biomed Solns. Check DNA cash flow quality score to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (ILA) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | 0.57x | ILA1.61 Million | ILA2.81 Million | ▲ +224.1% |
| 2023 | -0.46x | ILA-678.00K | ILA1.47 Million | ▼ -145.0% |
| 2022 | -0.19x | ILA-354.00K | ILA1.88 Million | ▲ +97.7% |
| 2021 | -8.12x | ILA-2.33 Million | ILA287.00K | ▼ -13914.7% |
| 2020 | -0.06x | ILA-611.00K | ILA10.54 Million | ▲ +63.9% |
| 2019 | -0.16x | ILA-1.37 Million | ILA8.55 Million | ▼ -52.9% |
| 2018 | -0.11x | ILA-1.66 Million | ILA15.81 Million | ▲ +50.4% |
| 2017 | -0.21x | ILA-1.91 Million | ILA8.99 Million | ▼ -80.2% |
| 2016 | -0.12x | ILA-14.30 Million | ILA121.59 Million | ▲ +72.7% |
| 2015 | -0.43x | ILA-15.57 Million | ILA36.10 Million | ▼ -8.6% |
| 2014 | -0.40x | ILA-10.99 Million | ILA27.68 Million | ▲ +29.5% |
| 2013 | -0.56x | ILA-5.17 Million | ILA9.19 Million | — |